Literature DB >> 8141574

Retain intermittent dosing of carbapenems.

H Hanberger, L E Nilsson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8141574      PMCID： PMC284416          DOI： 10.1128/AAC.38.1.159

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  9 in total

Review 1.  Continuous infusion of beta-lactam antibiotics.

Authors:  W A Craig; S C Ebert
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

2.  Subpopulations of variants resistant to imipenem in Pseudomonas aeruginosa.

Authors:  L Nilsson; M Nilsson; J Jendle
Journal:  J Antimicrob Chemother       Date:  1988-11       Impact factor: 5.790

Review 3.  Role of pharmacokinetics in the outcome of infections.

Authors:  G L Drusano
Journal:  Antimicrob Agents Chemother       Date:  1988-03       Impact factor: 5.191

4.  Ceftazidime versus imipenem-cilastatin as initial monotherapy for febrile neutropenic patients.

Authors:  R Liang; R Yung; E Chiu; P Y Chau; T K Chan; W K Lam; D Todd
Journal:  Antimicrob Agents Chemother       Date:  1990-07       Impact factor: 5.191

5.  Steady-state pharmacokinetics of imipenem in febrile neutropenic cancer patients.

Authors:  G L Drusano; K I Plaisance; A Forrest; C Bustamante; A Devlin; H C Standiford; J C Wade
Journal:  Antimicrob Agents Chemother       Date:  1987-09       Impact factor: 5.191

6.  Integration of pharmacokinetics and pharmacodynamics of imipenem in a human-adapted mouse model.

Authors:  U Flückiger; C Segessenmann; A U Gerber
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

7.  Post-antibiotic effect of beta-lactam antibiotics on gram-negative bacteria in relation to morphology, initial killing and MIC.

Authors:  H Hanberger; L E Nilsson; M Nilsson; R Maller
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-11       Impact factor: 3.267

Review 8.  Resistance to imipenem in Pseudomonas aeruginosa: clinical experience and biochemical mechanisms.

Authors:  J P Quinn; A E Studemeister; C A DiVincenzo; S A Lerner
Journal:  Rev Infect Dis       Date:  1988 Jul-Aug

Review 9.  Outpatient parenteral antibiotic therapy. Management of serious infections. Part I: Medical, socioeconomic, and legal issues. Selecting the antibiotic.

Authors:  W A Craig
Journal:  Hosp Pract (Off Ed)       Date:  1993-06
  9 in total
  3 in total

Review 1.  Comparative pharmacokinetics of the carbapenems: clinical implications.

Authors:  J W Mouton; D J Touzw; A M Horrevorts; A A Vinks
Journal:  Clin Pharmacokinet       Date:  2000-09       Impact factor: 6.447

Review 2.  Meropenem clinical pharmacokinetics.

Authors:  J W Mouton; J N van den Anker
Journal:  Clin Pharmacokinet       Date:  1995-04       Impact factor: 6.447

Review 3.  Continuous infusion of beta-lactam antibiotics.

Authors:  A P MacGowan; K E Bowker
Journal:  Clin Pharmacokinet       Date:  1998-11       Impact factor: 6.447
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.